COR — Cencora Inc
NYSE · Health Care · Health Care
- Latest Close
- $308.3
- 30-Day Move
- -9.8%
- Market Cap
- $63.2B
- Shares Outstanding
- 194,530,000
- P/E Ratio
- 38.88
- P/B Ratio
- 40.18
Analyst consensus: Buy · 18 analysts
Cencora Inc
A read-only Alphactor snapshot forCencora Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-22
Topline snapshot
Latest Close
$308.3
30-Day Move
-9.8%
Market Cap
$63.2B
Shares Outstanding
194,530,000
P/E Ratio
38.88
P/B Ratio
40.18
$308.30
-9.8%last 90 delayed daily bars
90D High
$376.92
90D Low
$304.33
Avg Volume
1,313,367
Gross margin is running at 3.6%, which gives a quick read on operating quality before you open the full model.
Net margin is 50.0%, useful for comparing COR against peers in Health Care.
COR is down 9.8% over the last 30 trading days shown on this page.
Latest operating income is $1.0B, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$2904.08
Rule of 40
10.3%
Latest Close
$308.3
30-Day Move
-9.8%
Market Cap
$63.2B
Shares Outstanding
194,530,000
P/E Ratio
38.88
P/B Ratio
40.18
ROE
103.1%
ROA
2.0%
Gross Margin
3.6%
Operating Margin
82.0%
Net Margin
50.0%
Debt / Equity
5.08
Current Ratio
0.9
Dividend Yield
76.8%
Latest Revenue
$85.9B
Revenue
$85.9B
Gross Profit
$3.1B
Operating Income
$1.0B
Net Income
$560M
Gross Margin
363.0%
Net Margin
50.0%
Current Ratio
0.90
Debt / Equity
5.08
Fair Value
$2904.08
Upside / Downside
+842.0%
Signal
Undervalued
Implied Growth
6.7%
DCF
$324.74
EPV
$145.28
EV/Rev
$8242.22
Growth Assumption
10.4%
Discount Rate
9.0%
Terminal Growth
2.0%
Base FCF
$3.2B
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Low growth priced in
Altman Z
4.90
Safe
Piotroski
6
Moderate (4-6)
Cash Conversion
2.49x
Rule of 40
10.3%
Concerning
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $238.6B | $2.8B | $1.7B | $2.2B |
| 2023-12-31 | $262.2B | $2.7B | $1.7B | $3.5B |
| 2024-12-31 | $294.0B | $3.2B | $1.5B | $3.0B |
| 2025-12-31 | $321.3B | $3.9B | $1.6B | $3.2B |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 5,785,036 | 0.03% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 4,889,309 | 0.03% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 4,011,151 | 0.02% | 2025-12-31 |
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 2,727,140 | 0.01% | 2025-12-31 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2,632,712 | 0.01% | 2026-01-31 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 2,467,340 | 0.01% | 2026-02-28 |
| iShares Trust-iShares Core S&P 500 ETF | 2,471,563 | 0.01% | 2026-02-28 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 2,255,480 | 0.01% | 2026-03-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Vanguard Group
Filed 2026-01-29
$8.0B
+0.9%
BlackRock
Filed 2024-05-10
$4.7B
--
FMR LLC (Fidelity)
Filed 2026-02-17
$1.8B
+64.9%
Geode Capital Management
Filed 2026-02-09
$1.8B
+3.2%
Invesco
Filed 2026-02-19
$1.3B
-2.3%
4.06
Consensus
Buy—
—
—
18
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.